Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients
In clinical trials and meta-analysis, atherosclerotic vascular events (AVEs) during treatment with immune-checkpoint inhibitors (ICIs) have been reported with low incidence. However, preclinical data suggest that these drugs can promote atherosclerosis inflammation and progression of atherosclerosis...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-05-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.652186/full |
| _version_ | 1818645621168406528 |
|---|---|
| author | Alessandro Inno Andrea Chiampan Laura Lanzoni Matteo Verzè Giulio Molon Stefania Gori |
| author_facet | Alessandro Inno Andrea Chiampan Laura Lanzoni Matteo Verzè Giulio Molon Stefania Gori |
| author_sort | Alessandro Inno |
| collection | DOAJ |
| description | In clinical trials and meta-analysis, atherosclerotic vascular events (AVEs) during treatment with immune-checkpoint inhibitors (ICIs) have been reported with low incidence. However, preclinical data suggest that these drugs can promote atherosclerosis inflammation and progression of atherosclerosis plaques, and there is now growing and convincing evidence from retrospective studies that ICIs increase the risk of atherosclerotic vascular events including arterial thrombosis, myocardial infarction and ischemic stroke. Prospective studies are needed to increase knowledge on long-term effect of ICIs or their combinations with other cardio-toxic drugs, but in the meantime a careful assessment and optimization of cardiovascular risk factors among patients treated with ICIs is advisable. |
| first_indexed | 2024-12-17T00:33:39Z |
| format | Article |
| id | doaj.art-25b4e55a8cb54664b25ee199f8400dab |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-17T00:33:39Z |
| publishDate | 2021-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-25b4e55a8cb54664b25ee199f8400dab2022-12-21T22:10:12ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2021-05-01810.3389/fcvm.2021.652186652186Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer PatientsAlessandro Inno0Andrea Chiampan1Laura Lanzoni2Matteo Verzè3Giulio Molon4Stefania Gori5Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Sacro Cuore Don Calabria, Verona, ItalyCardiology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Sacro Cuore Don Calabria, Verona, ItalyCardiology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Sacro Cuore Don Calabria, Verona, ItalyMedical Direction, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Sacro Cuore Don Calabria, Verona, ItalyCardiology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Sacro Cuore Don Calabria, Verona, ItalyMedical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Sacro Cuore Don Calabria, Verona, ItalyIn clinical trials and meta-analysis, atherosclerotic vascular events (AVEs) during treatment with immune-checkpoint inhibitors (ICIs) have been reported with low incidence. However, preclinical data suggest that these drugs can promote atherosclerosis inflammation and progression of atherosclerosis plaques, and there is now growing and convincing evidence from retrospective studies that ICIs increase the risk of atherosclerotic vascular events including arterial thrombosis, myocardial infarction and ischemic stroke. Prospective studies are needed to increase knowledge on long-term effect of ICIs or their combinations with other cardio-toxic drugs, but in the meantime a careful assessment and optimization of cardiovascular risk factors among patients treated with ICIs is advisable.https://www.frontiersin.org/articles/10.3389/fcvm.2021.652186/fullarterial thrombosisischemic strokemyocardial infarctionatherosclerosisPD-L1PD-1 |
| spellingShingle | Alessandro Inno Andrea Chiampan Laura Lanzoni Matteo Verzè Giulio Molon Stefania Gori Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients Frontiers in Cardiovascular Medicine arterial thrombosis ischemic stroke myocardial infarction atherosclerosis PD-L1 PD-1 |
| title | Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients |
| title_full | Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients |
| title_fullStr | Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients |
| title_full_unstemmed | Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients |
| title_short | Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients |
| title_sort | immune checkpoint inhibitors and atherosclerotic vascular events in cancer patients |
| topic | arterial thrombosis ischemic stroke myocardial infarction atherosclerosis PD-L1 PD-1 |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2021.652186/full |
| work_keys_str_mv | AT alessandroinno immunecheckpointinhibitorsandatheroscleroticvasculareventsincancerpatients AT andreachiampan immunecheckpointinhibitorsandatheroscleroticvasculareventsincancerpatients AT lauralanzoni immunecheckpointinhibitorsandatheroscleroticvasculareventsincancerpatients AT matteoverze immunecheckpointinhibitorsandatheroscleroticvasculareventsincancerpatients AT giuliomolon immunecheckpointinhibitorsandatheroscleroticvasculareventsincancerpatients AT stefaniagori immunecheckpointinhibitorsandatheroscleroticvasculareventsincancerpatients |